Peloso Andrea, Tamburrini Riccardo, Edgar Lauren, Wilm Bettina, Katari Ravi, Perin Laura, Murray Patricia, Orlando Giuseppe
General Surgery, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
Wake Forest School of Medicine, Winston Salem, USA.
Eur J Pharmacol. 2016 Nov 5;790:21-27. doi: 10.1016/j.ejphar.2016.07.038. Epub 2016 Jul 22.
Chronic and end stage renal disease (ESRD) have reached pandemic levels and pose a substantial public health burden. Unfortunately, available therapies lack efficacy in preventing progression to its end stage phase. Regenerative medicine promises to restore function of diseased organs among which the kidney, through two possible approaches: firstly, the maximization of the innate ability of tissues to repair or regenerate following injury; secondly, the ex vivo bio-fabrication of the organ in question. When regenerative medicine is applied to the setting of chronic or ESRD, it is intuitive that endeavors to improve renal repair, promote nephrogenesis in damaged kidneys, or the de novo engineering of transplantable kidneys, could have a major impact on the current management of this pandemic. Among the different regenerative medicine technologies currently under development, cell-on-scaffold seeding technology (CSST) - involving cells seeded throughout supporting scaffold structures made from biomaterials - is the most favorable candidate in the context of realistic clinical application. In this review, we outline and describe current investigations taking place in the field of CSST as it pertains to the restoration of kidney function.
慢性肾脏病和终末期肾病（ESRD）已达到大流行程度，并构成了沉重的公共卫生负担。不幸的是，现有的治疗方法在预防疾病进展至终末期方面缺乏疗效。再生医学有望通过两种可能的方法恢复患病器官的功能，其中包括肾脏：第一，最大化组织在损伤后修复或再生的固有能力；第二，对相关器官进行体外生物制造。当再生医学应用于慢性肾脏病或ESRD时，可以直观地看出，致力于改善肾脏修复、促进受损肾脏的肾生成或对可移植肾脏进行从头工程设计，可能会对当前这一流行病的管理产生重大影响。在目前正在开发的不同再生医学技术中，支架细胞接种技术（CSST）——将细胞接种在由生物材料制成的支撑支架结构中——在实际临床应用背景下是最有希望的候选技术。在这篇综述中，我们概述并描述了CSST领域目前有关恢复肾功能的研究。
